A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

Exclusion Criteria

• •Received treatment with any local or systemic antineoplastic therapy within 3 weeks or 5× the plasma half-life prior to first dose of ZH9
• •Major surgery or radiation within the 3 weeks prior to Screening (TURBT is not considered major surgery)
• •Concurrent urinary tract infection or history of clinically significant polyuria
• •Symptoms consistent with typhoid
• •Evidence of infection within 2 weeks of the first dose of ZH9
• •Significant 12-lead electrocardiogram abnormalities
• •History of malignancy within the previous 12 months
• •History of allogeneic tissue/solid organ transplant